Company research
OptimizeRx Corp
CIK 1448431Updated Sep 24, 2026
SecurityOPRX · NASDAQ · equity
OPRX price & chart
Loading TradingView…
NASDAQ:OPRX on TradingView ↗About the company
OptimizeRx is a leading healthcare technology company that’s redefining how life science brands connect with patients and healthcare providers. Our platform combines innovative artificial intelligence (AI)-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. By bridging the gap between HCP and DTC strategies, we empower brands to create synchronized marketing solutions that drive faster treatment decisions and improved patient outcomes.
In the news
OptimizeRx Sets Second Quarter 2026 Conference Call for August 12, 2026, at 4:30 p.m. ET ↗
Recent filings
4 filing
4 filing
S-8 filing
10-Q filing
Results of Operations and Financial Condition · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure
Items 2.02, 5.02, 7.01, 9.01
Show 5 more recent filings
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Submission of Matters to a Vote of Security Holders
Items 5.02, 5.07, 9.01
4 filing
4 filing
4 filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 176,918,000Source | 171,168,000Source | 183,373,898Source | 134,651,185Source |
| Property, Plant and Equipment, NetUSD | 106,000Source | 150,000Source | 149,407Source | 137,448Source |
| GoodwillUSD | 70,869,000Source | 70,869,000Source | 78,357,074Source | 22,673,820Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 23,365,000Source | 13,380,000Source | 13,852,456Source | 18,208,685Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 37,752,000Source | 38,212,000Source | 36,253,214Source | 22,155,301Source |
| Assets, CurrentUSD | 64,715,000Source | 53,971,000Source | 54,330,892Source | 98,576,635Source |
| Prepaid Expense and Other Assets, CurrentUSD | — | 2,379,000Source | 3,189,468Source | — |
| Operating Lease, Right-of-Use AssetUSD | 404,000Source | 366,000Source | 572,895Source | 235,320Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 48,624,000Source | 54,170,000Source | 56,820,724Source | 8,540,408Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | — | — | — |
| Common Stock, Value, IssuedUSD | 20,000Source | 20,000Source | 19,899Source | 18,289Source |
| Additional Paid in CapitalUSD | 207,512,000Source | 201,348,000Source | 190,792,980Source | 172,785,800Source |
| Retained Earnings (Accumulated Deficit)USD | -79,236,000Source | -84,368,000Source | -64,257,964Source | -46,692,098Source |
| Stockholders' Equity Attributable to ParentUSD | 128,294,000Source | 116,998,000Source | 126,553,174Source | 126,110,777Source |
| Liabilities and EquityUSD | 176,918,000Source | 171,168,000Source | 183,373,898Source | 134,651,185Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 21,264,000Source | 18,654,000Source | 17,881,125Source | 8,395,876Source |
| Operating Lease, Liability, CurrentUSD | 193,000Source | 168,000Source | 221,625Source | 89,902Source |
| Operating Lease, Liability, NoncurrentUSD | 234,000Source | 209,000Source | 371,438Source | 144,532Source |
| Deferred Income Tax Liabilities, NetUSD | 5,705,000Source | 4,491,000Source | 4,337,424Source | — |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 11,591,000Source | 8,486,000Source | 7,754,781Source | 2,601,246Source |
| Deferred Revenue, CurrentUSD | — | — | 171,841Source | 164,309Source |
| Deferred Tax Liabilities, NetUSD | 5,705,000Source | 271,000Source | 12,701,424Source | 2,330,000Source |
| Long-term Debt, Excluding Current Maturities | — | — | — | — |
| Long-term Debt, Current MaturitiesUSD | 4,255,000Source | 2,000,000Source | 2,000,000Source | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 21,421,000Source | 30,816,000Source | 34,230,737Source | — |
| Short-term InvestmentsUSD | 0Source | — | — | 55,931,821Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | — | — | 2,401,628Source | 2,022,029Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 6,962,000Source | 11,467,000Source | 13,717,333Source | 15,745,822Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | -460,000Source | 2,168,000Source | 8,712,954Source | -2,281,773Source |
| Increase (Decrease) in Accounts PayableUSD | -520,000Source | -72,000Source | -1,320,150Source | 943,171Source |
| Deferred Income Tax Expense (Benefit)USD | 1,215,000Source | 153,000Source | 1,206,713Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 18,715,000Source | 4,889,000Source | -7,239,153Source | 10,654,078Source |
| Cash flows from investing activities: | ||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | — | 82,947,264Source | 2,000,000Source |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 68,000Source | -450,000Source | -25,336,865Source | -58,176,386Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 58,000Source | 112,000Source | 87,073Source | 81,005Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | 911,000Source | — | — |
| Payments for Repurchase of Common StockUSD | — | — | 7,522,426Source | 20,024,258Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -8,798,000Source | -4,911,000Source | 28,219,789Source | -18,950,777Source |
| Repayments of Long-term DebtUSD | 8,000,000Source | 4,000,000Source | 1,710,000Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 9,985,000Source | — | -4,356,229Source | -66,473,085Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 23,365,000Source | 13,380,000Source | 13,852,456Source | 18,208,685Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 4,184,000Source | 6,203,000Source | 1,212,619Source | — |
| Income Taxes Paid, NetUSD | 1,760,000Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 6,962,000Source | — | — | 15,745,822Source |
| Amortization of Debt Issuance CostsUSD | 1,110,000Source | 835,000Source | 210,737Source | — |
| Amortization of Intangible AssetsUSD | 4,225,000Source | 4,218,000Source | — | — |
| DepreciationUSD | 102,000Source | 111,000Source | 99,849Source | 85,725Source |
| Disposal Group, Not Discontinued Operation, Gain (Loss) on DisposalUSD | — | — | -2,142,319Source | — |
| Financing Interest ExpenseUSD | — | — | 5,000,000Source | — |
| Gain (Loss) on Disposition of Other AssetsUSD | — | — | -2,142,319Source | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | -1,310,004Source | — |
| GoodwillUSD | 70,869,000Source | 70,869,000Source | 78,357,074Source | 22,673,820Source |
| Goodwill, Impairment LossUSD | 0Source | — | — | — |
| Impairment of Intangible Assets (Excluding Goodwill)USD | 368,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | 1,818,000Source | 725,000Source | -7,597,922Source | — |
| InterestExpenseNonoperatingUSD | 5,294,000Source | 6,160,000Source | — | — |
| Investment Income, InterestUSD | 353,000Source | 329,000Source | 2,191,689Source | — |
| Net Income (Loss) Attributable to ParentUSD | 5,132,000Source | -20,110,000Source | -17,565,866Source | -11,438,440Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | 5,132,000Source | -20,110,000Source | -17,565,866Source | -11,438,440Source |
| Nonoperating Income (Expense)USD | -4,743,000Source | -5,679,000Source | 1,237,926Source | — |
| Operating ExpensesUSD | 61,902,000Source | 73,084,000Source | 69,301,631Source | 51,257,558Source |
| Other Nonoperating Income (Expense)USD | — | — | — | 852,298Source |
| Proceeds from Stock Options ExercisedUSD | 352,000Source | — | — | 1,073,481Source |
| Stock or Unit Option Plan ExpenseUSD | — | — | 8,956,198Source | 12,528,706Source |
| Unrealized Gain (Loss) on InvestmentsUSD | — | — | 12,291,169Source | 35,121,055Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 109,429,000Source | 92,127,000Source | — | — |
| Cost of Goods and Services Sold | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | — | — | — | 33,489,707Source |
| Operating Income (Loss)USD | 11,693,000Source | -13,706,000Source | -26,401,714Source | -12,290,738Source |
| Other Nonoperating Income (Expense)USD | — | — | — | 852,298Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | 6,950,000Source | -19,385,000Source | — | -11,438,440Source |
| Income Tax Expense (Benefit)USD | 1,818,000Source | 725,000Source | -7,597,922Source | — |
| Net Income (Loss) Attributable to ParentUSD | 5,132,000Source | -20,110,000Source | -17,565,866Source | -11,438,440Source |
| Earnings Per Share, BasicUSD per share | 0.28Source | -1.1Source | -1.03Source | -0.64Source |
| Earnings Per Share, DilutedUSD per share | 0.27Source | -1.1Source | -1.03Source | -0.64Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 18,555,343Source | 18,292,935Source | 17,124,801Source | 17,783,992Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 18,998,463Source | 18,292,935Source | 17,124,801Source | 17,783,992Source |
| Interest Expense (non-operating)USD | 5,294,000Source | 6,160,000Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 4,225,000Source | 4,218,000Source | — | — |
| Current Income Tax Expense (Benefit)USD | 603,000Source | 572,000Source | -97,452Source | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | 4,327,000Source | 4,329,000Source | 2,401,628Source | 2,022,029Source |
| Financing Interest ExpenseUSD | — | — | 5,000,000Source | — |
| Goodwill, Impairment LossUSD | 0Source | — | — | — |
| Gross ProfitUSD | 73,595,000Source | 59,378,000Source | 42,899,917Source | 38,966,820Source |
| Income (Loss) Attributable to Parent, before TaxUSD | — | — | -25,163,788Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | 6,732,000Source | — | — | — |
| Interest ExpenseUSD | — | — | 1,453,764Source | — |
| Investment Income, InterestUSD | 353,000Source | 329,000Source | 2,191,689Source | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | 5,132,000Source | -20,110,000Source | -17,565,866Source | -11,438,440Source |
| Nonoperating Income (Expense)USD | -4,743,000Source | -5,679,000Source | 1,237,926Source | — |
| Operating ExpensesUSD | 61,902,000Source | 73,084,000Source | 69,301,631Source | 51,257,558Source |
| Other General and Administrative ExpenseUSD | 50,245,000Source | 49,799,000Source | 775,548Source | — |
| Research and Development ExpenseUSD | 0Source | — | — | — |
Filing attachments
ea028547301ex99-1.htm · 8-K · 2026-04-09
EX-99.1 2 ea028547301ex99-1.htm PRESS RELEASE, DATED APRIL 8, 2026 Exhibit 99.1 OptimizeRx Appoints Mary Varghese Presti to Board of Directors Microsoft Health & Life Sciences COO brings expertise in scaling healthcare platforms, commercializing new technologies, and driving operational efficiency WALTHAM, MA - April 8, 2026 (GLOBE NEWSWIRE) - OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare solutions helping life sciences companies reach and engage heal…
Read attachment ↗ea025374101ex99-1_optimize.htm · 8-K · 2025-08-19
EX-99.1 3 ea025374101ex99-1_optimize.htm OPTIMIZERX CORPORATION ANNOUNCES LEADERSHIP TEAM ADVANCEMENTS TO ACCELERATE STRATEGIC GROWTH Exhibit 99.1 OptimizeRx Corporation Announces Leadership Team Advancements to Accelerate Strategic Growth WALTHAM, MA - August 19, 2025 - OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced organiza…
Read attachment ↗ea024660201ex99-1_optimize.htm · 8-K · 2025-06-24
EX-99.1 2 ea024660201ex99-1_optimize.htm PRESS RELEASE, DATED JUNE 24, 2025 Exhibit 99.1 OptimizeRx Corporation Appoints CEO Steve Silvestro to Board of Directors WALTHAM, MA - June 24, 2025 - OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced the appointment of Steve Silvestro, currently serving as the Company’s Chief Executive …
Read attachment ↗ea023886601ex99-1_optimize.htm · 8-K · 2025-04-18
EX-99.1 2 ea023886601ex99-1_optimize.htm PRESS RELEASE OF OPTIMIZERX CORPORATION ISSUED ON APRIL 18, 2025 Exhibit 99.1 OptimizeRx Corporation Announces Plan for Additional Board of Directors Refreshment WALTHAM, MA - April 18, 2025 - OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that, as part of OptimizeRx’s ongoing process …
Read attachment ↗ea023405901ex99-1_optimize.htm · 8-K · 2025-03-12
EX-99.1 2 ea023405901ex99-1_optimize.htm PRESS RELEASE, DATED MARCH 12, 2025 Exhibit 99.1 OptimizeRx Reports Strong Fourth Quarter and Full Year 2024 Financial Results Q4 revenue of $32.3 million, increasing 14% year-over-year Q4 gross profit increased 23% year-over-year to $22.0 million with gross margin of 68% Company generated revenue from 48 DAAP deals in 2024, up from 24 in 2023 ──────────────────────────────────────────────────────────────────────────── Waltham, MA. - March…
Read attachment ↗ea023370201ex99-1_optimize.htm · 8-K · 2025-03-10
EX-99.1 3 ea023370201ex99-1_optimize.htm PRESS RELEASE, DATED MARCH 10, 2025 Exhibit 99.1 OptimizeRx Corporation Appoints Stephen Silvestro as Chief Executive Officer Silvestro has a demonstrated record of accelerating revenue growth, expanding brand relevance, and building a market-leading team WALTHAM, MA - March 10, 2025 - OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare pr…
Read attachment ↗